JVR_2024v14n5

Journal of Vaccine Research 2024, Vol.14, No.5, 231-242 http://medscipublisher.com/index.php/jvr 241 Niyomnaitham S., Toh Z.Q., Wongprompitak P., Jansarikit L., Srisutthisamphan K., Sapsutthipas S., Jantraphakorn Y., Mingngamsup N., Licciardi P.V., and Chokephaibulkit K., 2022, Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: an open-label randomized study in healthy Thai adults, Human Vaccines and Immunotherapeutics, 18(6): 2091865. https://doi.org/10.1080/21645515.2022.2091865 PMID: 35816053 PMCID: PMC9746495 Notarte K.I., Guerrero-Arguero I., Velasco J., Ver A.T., de Oliveira M.H.S., Catahay J.A., Khan M.S.R., Pastrana A., Juszczyk G., Torrelles J.B., Lippi G., Martínez-Sobrido L., and Henry B.M., 2021, Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review, Journal of Medical Virology, 94(7): 2939-2961. https://doi.org/10.1002/jmv.27688 PMID: 35229324 PMCID: PMC9088566 Paul P., El-Naas A., Hamad O., Salameh M.A., Mhaimeed N., Laswi I., Abdelati A.A., Alanni J., Khanjar B., Al-Ali D., Pillai K.V., Elshafeey A., Alroobi H., Burney Z., Mhaimeed O., Bhatti M., Sinha P., Almasri M., Aly A., Bshesh K., Chamseddine R., Khalil O., D’Souza A., Shree T., Mhaimeed N., Yagan L., and Zakaria D., 2023, Effectiveness of the pre-Omicron COVID-19 vaccines against omicron in reducing infection, hospitalization, severity, and mortality compared to delta and other variants: a systematic review, Human Vaccines and Immunotherapeutics, 19(1): 2167410. https://doi.org/10.1080/21645515.2023.2167410 PMID: 36915960 PMCID: PMC10054360 Poh X.Y., Tan C.W., Lee I.R., Chavatte J.M., Fong S.W., Prince T., Hartley C., Yeoh A.Y.Y., Rao S., Chia P.Y., Ong S.W.X., Lee T.H., Sadarangani S.P., Lin R.J.H., Lim C., Teo J., Lim D.R.X., Chia W., Hiscox J.A., Ng L.F.P., Ren E.C,, Lin R.T.P., Rénia L., Lye D.C., Wang L.F., and Young B.E., 2022, Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial, Clinical Infectious Diseases, 75(12): 2088-2096. https://doi.org/10.1093/cid/ciac345 PMID: 35543372 PMCID: PMC9129205 Pratama N.R., Wafa I.A., Budi D.S., Sutanto H., Asmarawati T.P., Effendi G.B., and Wungu C.D.K., 2022, Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): a systematic review with meta-analysis and meta-regression, Vaccines, 10(12): 2180. https://doi.org/10.3390/vaccines10122180 PMID: 36560590 PMCID: PMC9783108 Rudan I., Adeloye D., and Sheikh A., 2022, COVID-19: vaccines, efficacy and effects on variants, Current Opinion in Pulmonary Medicine, 28: 180-191. https://doi.org/10.1097/MCP.0000000000000868 Sharif N., Alzahrani K.J., Ahmed S.N., and Dey S.K., 2021, Efficacy, Immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis, Frontiers in Immunology, 12: 714170. https://doi.org/10.3389/fimmu.2021.714170 Sun W.Q., He L.H., Zhang H., Tian X.D., Bai Z.H., Sun L., Yang L.M., Jia X.J., Bi Y.H., Luo T.R., Cheng G., Fan W.H., Liu W.J., and Li, J., 2021, The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice, Signal Transduction and Targeted Therapy, 6(1): 340. https://doi.org/10.1038/s41392-021-00750-w PMID: 34504054 PMCID: PMC8426336 Tao K., Tzou P.L., Nouhin J., Gupta R.K., de Oliveira T., Pond S.L.K., Fera D., and Shafer R.W., 2021, The biological and clinical significance of emerging SARS-CoV-2 variants, Nature Reviews Genetics, 22(12): 757-773. https://doi.org/10.1038/s41576-021-00408-x PMID: 34535792 PMCID: PMC8447121 Thakur S., Sasi S., Pillai S.G., Nag A., Shukla D., Singhal R., Phalke S., and Velu G.S.K., 2022, SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines, Frontiers in Medicine, 9: 815389. https://doi.org/10.3389/fmed.2022.815389 PMID: 35273977 PMCID: PMC8902153 Thompson M.G., Burgess J.L., Naleway A.L., Tyner H.L., Yoon S.K., Meece J., Olsho L.E.W., Caban-Martinez A.J., Fowlkes A., Lutrick K., Kuntz J.L., Dunnigan K., Odean M.J., Hegmann K.T., Stefanski E., Edwards L.J., Schaefer-Solle N., Grant L., Ellingson K., Groom H.C., Zunie T., Thiese M.T., Ivacic L., Wesley M.G., Lamberte J.M., Sun X.X., Smith M.E., Phillips A.L., Groover K.D., Yoo Y.M., Gerald J., Brown R.T, Herring M.K., Joseph G., Beitel S., Morrill T.C., Mak J., Rivers P., Harris K.M., Hunt D.R., Arvay M.L., Kutty P., Fry A.M., and Gaglani M., 2021, Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-Eight U.S, Locations, December 2020-March 2021, Morbidity and Mortality Weekly Report, 70(13) 495-500. https://doi.org/10.15585/mmwr.mm7013e3 PMID: 33793460 PMCID: PMC8022879 Wang P.F., Nair M.S., Liu L.H., Iketani S., Luo Y., Guo Y.C., Wang M., Yu J., Zhang B.S., Kwong P.D., Graham B.S., Mascola J.R., Chang J.Y., Yin M.T., Sobieszczyk M., Kyratsous C.A., Shapiro L., Sheng Z.Z., Huang Y.X., and Ho D.D., 2021, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature, 593(7857): 130-135. https://doi.org/10.1038/s41586-021-03398-2 PMID: 33684923

RkJQdWJsaXNoZXIy MjQ4ODYzNQ==